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Endometrial cancers exhibit a diﬀerent mechanism of tumorigenesis and progression depending on histopathological and
clinical types. The most frequently altered gene in estrogen-dependent endometrioid endometrial carcinoma tumors is PTEN.
Microsatellite instability is another important genetic event in this type of tumor. In contrast, p53 mutations or Her2/neu
overexpression are more frequent in non-endometrioid tumors. On the other hand, it is possible that the clear cell type may arise
from a unique pathway which appears similar to the ovarian clear cell carcinoma. K-ras mutations are detected in approximately
15%–30% of endometrioid carcinomas, are unrelated to the existence of endometrial hyperplasia. A β-catenin mutation was
detectedinabout20%ofendometrioidcarcinomas,butisrareinserouscarcinoma.Telomereshorteningisanotherimportanttype
of genomic instability observed in endometrial cancer. Only non-endometrioid endometrial carcinoma tumors were signiﬁcantly
associated with critical telomere shortening in the adjacent morphologically normal epithelium. Lynch syndrome, which is
an autosomal dominantly inherited disorder of cancer susceptibility and is characterized by a MSH2/MSH6 protein complex
deﬁciency, is associated with the development of non-endometrioid carcinomas.
1.Introduction
Endometrial cancer is the most common cancer of the
female reproductive tract with 150,000 new cases diagnosed
annually worldwide. Approximately 90% of endometrial
cancers are sporadic, and the remaining 10% are hereditary.
Bokhman have generally categorized endometrial cancer
into two broad groups of tumors using both clinical and
histopathological variables: estrogen-dependent endometri-
oid endometrial carcinomas (EECs), or type I, and non-
endometrioid endometrial carcinomas (NEECs), or type II
tumors (Table 1)[ 1]. It should be noted that this model is
not strict, and only a minority of endometrial cancer may
exhibit shared characteristics. For example, mixed serous
and endometrioid tumors are being increasingly recognized.
Approximately 70% to 80% of new cases are classiﬁed as
EECs, andother10%to20%aredesignatedasNEEC tumors
[1]. EECs are strongly associated with the estrogen-related
pathway and arise in association with unopposed estrogen
stimulation [2]. In contrast, NEECs are unrelated to the
estrogen pathways and arise in the background of atrophic
endometrium [3]. EECs typically occur in premenopausal
and younger postmenopausal women and are usually low-
grade and have a favorable outcome, whereas NEECs occur
in older postmenopausal women. In addition, NEECs tend
to predict a high tumor grade and poor patient prognosis
[4, 5]. The ﬁrst pathway is associated with endometrioid
histopathology, and the second is linked to the serous and
clear cell subtypes. The precursors of these subtypes are
known as atypical hyperplasia and endometrial intraepithe-
lial carcinoma (EIC), respectively. Clear cell cancer, classiﬁed
as an NEEC, is associated with atypical hyperplasia as well as
EIC.
Recent reports suggest that histological diﬀerences may
be associated with distinct molecular genetic alterations.
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carcinomas are likely to develop as the result of a multistep
process of oncogenic activation and tumor suppressor inac-
tivation (Table 2)[ 6].
2. Gain-of-FunctionGeneticEvents
The genes implicated in the gain-of-function events are
oncogenes. The important genes related to endometrial
oncogenesis or progressions are the K-ras,B-raf, Her2/neu, β-
catenin, AKT,a n dFGFR2 oncogenes.
2.1. K-ras and B-raf. K-ras proto-oncogene mutations are
detected in approximately 10%–30% of endometrioid car-
cinomas [7]. K-ras mutations have been identiﬁed in
endometrial hyperplasias, although at a lower frequency
than in carcinomas [8–10]. According to these studies, the
gain of the K-ras function may represent an early event
in endometrioid-type tumorigenesis. During tumorigenesis,
activated RAS is usually associated with enhanced prolifer-
ation, transformation, and cell survival. Conversely, K-ras
mutations occur with equal frequency in tumors with and
without hyperplasia, and the epidemiologic results seem to
suggest that K-ras activation is associated with malignant
progression of endometrial tumors without the need for
transition via hyperplasia [11]. In contrast to endometrioid
carcinomas, K-ras mutations are extremely rare among
serous and clear cell carcinomas [12, 13].
A correlation between colon cancer development and
Ras/Raf point mutations in the MAP kinase pathway drives
the malignant transformation of colon cancer. In contrast,
only a few reports have shown B-raf mutations in patients
with endometrial cancer. Feng et al. identiﬁed a B-raf
mutation in 21% of patients with endometrial cancers and
suggest that the mutation correlated with decreased hMLH1
expression [14]. In contrast, Salevesen et al. described a B-raf
mutation in only 2% of endometrial cancers; and Kawaguchi
et al. and Mizumoto et al. reported no mutation in the
patients with endometrial cancer [15–17]. Therefore, a con-
sensus about the role of B-raf mutation in the development
of endometrial cancer has not yet been developed.
2.2.Her2/neu. Her2/neu(erbB2)isanoncogenethatencodes
a transmembrane receptor tyrosine kinase involved in cell
signaling. Either the overexpression or gene ampliﬁcation
of Her2/neu proto-oncogene activates receptor and soluble
tyrosine kinases. Her2/neu overexpression is detected in
about 10%–20% of Grades 2 and 3 endometrioid carcinoma
[9, 18, 19]. These studies suggest that Her2/neu overexpres-
sion in endometrioid carcinoma characterizes late progres-
sion and diﬀerentiation events. Her2/neu overexpression is
detected in approximately 9%–30% of serous carcinomas
[20]. Elucidation of the role of Her2/neu in these pathogenic
tumor types, therefore, requires further study.
2.3. β-Catenin. β-catenin, a component of the E-cadherin
family of proteins, is essential for cell diﬀerentiation and
maintenance of normal tissue architecture, and plays an
important role in signal transduction. β-catenin also acts as
a downstream transcriptional activator in the Wnt signal
transduction pathway. A β-catenin mutation results in the
stabilization of proteins that are degradation resistant, thus
resulting in cytoplasmic and nuclear β-catenin accumulation
and constitutive target gene activity. The accumulation of β-
catenin is demonstrated by immunohistochemistry. Several
studies have analyzed endometrial cancers, showing that
nuclear accumulation of β-catenin is signiﬁcantly more
common in endometrioid lesions (31% to 47%) compared
to nonendometrioid histologies (0% to 3%) [21]. In another
report, β-catenin nuclear accumulation was more frequent
in endometrial hyperplasias than in endometrial carcinoma
samples,suggestingaβ-cateninroleintheearlydevelopment
of this tumor type [22]. In fact, alterations in β-catenin
havebeendescribedinendometrialhyperplasiathatcontains
squamous metaplasia or morules. Koul et al. found that
all β-catenin mutated tumors were estrogen-receptor (ESR)
positiveandmostwereprogesterone-receptor(PgR)positive,
thussuggestingadependenceonestrogenstimulationduring
endometrial carcinogenesis [11]. In contrast, there is no
correlation between β-catenin mutations and Microsatellite
Instability (MI) or K-ras or PTEN mutations.
2.4. AKT. The phosphatidylinositol 3-kinase (PI3K) AKT
pathway is activated in many human cancers and plays a
key role in cell proliferation and survival. PIK3CA mutations
frequently occur with other genetic alterations such as
Her2/neu, K-ras, and PTEN in several types of tumors.
Endometrial cancer is known to possess various genes alter-
ations which activate the PI3K-AKT pathway. The frequency
of mutations for PIK3CA in endometrial cancer is reported
to be 28% [23]. However, Shoji et al. reported that AKT1
(E17K) mutations were detected in 2 out of 89 tissue samples
and 0 out of 12 cell lines [24]. They suggested that AKT1
mutations might be mutually exclusive from other PI3K-
AKT activating alterations, although PIK3CA mutations
frequently coexist with other gene aberrations. Additional
mutations in AKT family members in endometrial cancers
were reported in AKT2 (D399N, 426T, and 141T) and in
AKT3 (E438D) [25]. Taken together, studies found that 5
out of 41 endometrial cancers have mutations in AKT family
members at a frequency of approximately 12%.
2.5. FGFR2. Alterations in the ﬁbroblast growth factor
receptor 2 (FGFR2) gene causes the receptors to become
active, leading to cell proliferation. Byron et al. reported
mutations in FGFR2 in 10% of primary uterine tumor sam-
ples[26].Mutationswereobservedin 16%ofthe endometri-
oid histology subtype tumors. In primary endometrioid
endometrial cancers, FGFR2 and K-ras mutations were
mutually exclusive. Conversely, FGFR2 mutations were seen
togetherwithPTEN loss-of-functionmutations.Theauthors
alsoshowedthatendometrialcancercelllineswithactivating
FGFR2 mutations are selectively sensitive to the pan-FGFR
inhibitor, PD173074 [27]. In addition, upregulation of FGF2
mRNA expression was observed in endometrial cancer
specimens[28].ThesedatasuggestthatinvestigationoftheseObstetrics and Gynecology International 3
Table 1: Clinical and pathological features of endometrial carcinoma.
Type I (EEC) Type II (NEEC)
Age Pre- and perimenopausal Postmenopausal
Behavior Stable Progressive
Grade Low High
Hyperplasia-precursor Present Absent
Unopposed estrogen Present Absent
Myometrial invasion Minimal Deep
Speciﬁc Subtypes Endometrioid carcinoma Non-endometrioid carcinoma
Prevalence 70–80% 10–20%
Risk factors Obesity, anovulation, nulliparity and exogenous estrogen exposure In atropic endometrium
Table 2: Genetics features of endometrial carcinoma.
EEC NEEC
Gain-of Function
K-ras 15–30% 0–5%
Her2/neu 10–20% 9–30%
β-Catenin 31–47% 0–3%
Loss-of Function
PTEN 35–50% 10%
P53 10–20% 90%
Genomic instability (microsatellite) 20–40% 0-5%
agents may be therapeutically beneﬁcial for endometrial
cancer patients.
3. Loss-of-Function GeneticEvents
3.1. PTEN. Endometrial carcinomas are characterized by a
varietyofgeneticalterations,butthemostfrequentalteration
is in the PTEN gene. PTEN, located at chromosome 10q23,
encodes a protein and lipid phosphatase which behaves as
a tumor suppressor gene. PTEN inactivation is induced by
mutations that lead to a loss of expression and is induced
to a lesser extent by a loss of heterozygosity. The PTEN
protein has both lipid and protein phosphatase activities,
with each serving diﬀerent functions. The lipid phosphatase
activity of PTEN induces cell cycle arrest at the G1/S
checkpoint. In addition, the upregulation of proapoptotic
mechanismsinvolvingAKT-dependentmechanismsismedi-
ated through PTEN, as is the downregulation of anti-
apoptotic mechanisms through Bcl-2 [29–31]. PTEN further
acts in opposition to PI3K to control levels of phosphory-
lated AKT [23, 32] .AP I 3 Km u t a t i o ni ss e e ni n3 6 %o f
endometrioidendometrialcancersandiscommonintumors
that also carry the PTEN mutation. The protein phosphatase
activity of PTEN is involved in the inhibition of focal
adhesion formation, cell spread, and migration, as well as
the inhibition of growth-factor-stimulated MAPK signaling
[33]. The PTEN gene, which acts as a tumor suppressor
gene, is present in individuals and causes increased cancer
susceptibility, including those with Cowden’s syndrome.
PTEN mutations are the most frequent genetic lesions in
endometrial adenocarcinomas of the endometrioid subtype.
PTEN mutations are reported in 25%–83% of tumors, more
frequently in endometrioid carcinomas and microsatellite
unstable tumors, and are, thus, the most frequent genetic
alteration reported in cancers [34]. PTEN gene alterations
are associated with metastatic behavior and advanced stage
in other cancer types. In contrast, the loss of PTEN
function is an early event in endometrial tumorigenesis.
Several groups have described a concordance between MI
status and PTEN mutations; the mutations occur in 60%–
86% of MI-positive endometrial carcinoma EEC cases, but
only occur in 24%–35% of MI-negative tumors. Genetic
alterations that account for PTEN protein inactivation
include various mutations, a loss of heterozygosity (LOH),
or promoter hypermethylation, with mutations occurring
the most frequently [30]. PTEN promoter methylation is
observed in 19% of cancers and is signiﬁcantly associated
with metastatic disease [35]. Kim et al. reported that PTEN
and K-ras double-mutant mice (Ptend/dK-rasG12D) exhibited
dramatically accelerated endometrial cancer development
compared to cancers formed from a single PTEN or K-ras
gene mutation [36]. These results suggest a synergistic eﬀect
of dysregulation of the PTEN and K-ras signaling pathways
during endometrial tumorigenesis.
3.2. P53. The p53 gene is located on chromosome 17 and is
important in preventing the propagation of cells with dam-
aged DNA. p53 mutations or TP53 overexpression is twice as
frequent in tumors without hyperplasia (estrogen unrelated)
than in those with hyperplasia (estrogen related) [11, 37].
This is consistent with other data in which the most striking
geneticalteration,presentinabout90%ofserouscarcinomas
(estrogen-unrelated NEEC), is a p53 mutation [38]. In other
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between p53 alterations and non-endometrioid histology
type,high-gradetumors,andtheabsenceoftheprogesterone
receptor [39]. On the other hand, p53 genetic alterations
were observed in 17% of endometrioid carcinomas, which
were primarily Grade 3 [40]. The exact mechanisms causing
this mutation are still not well characterized. In response to
DNA damage, nuclear P53 accumulates and causes cell cycle
arrest by inhibiting Cyclin D1 phosphorylation of the Rb
gene and thereby promotes apoptosis. Therefore, mutated
P53 results in a nonfunctional protein that accumulates
in the cell and acts as a dominant negative inhibitor of
wild-type P53, leading to propagation of aberrant cells.
p53 mutations in endometrioid carcinoma are a late event
during progression or diﬀerentiation. P53 alterations play a
relativelyminorroleinclearcelltypeendometrialcarcinoma
in comparison to the serous type [41]. p53 mutations are
also rarely observed in ovarian clear cell adenocarcinomas
in comparison to endometrioid adenocarcinomas [42]. As
a result, it is possible that the pathogenesis of clear cell
carcinoma in the female genital tract arises from a unique
pathway [43].
4. GenomicInstability
The most important types of genomic instability in endome-
trial cancers are MI and chromosomal aneuploidy. DNA
mismatch repair (MMR) deﬁciency, detected as MI, is the
mostcommonmolecularphenotypeinendometrioidcancer,
as PTEN t u m o rs u p p r e s s o rg e n em u t a t i o n s .M Ii ss e e ni n
cancers (colonic, endometrial, and others) of patients with
hereditary nonpolyposis colon cancer (HNPCC) and is also
present in 28% of sporadic endometrioid cancers but is
not present in serous cancers [40]. MI is distributed almost
equally among the three histopathological tumor grades of
endometrioid cancers. However, MI is rare in the clear cell
type [44]. HNPCC patients with endometrial cancers have
an inherited germline mutation in MLH-1, MSH-2, MSH-
6,o rPMS-2, but endometrial cancer only develops after the
instauration of a deletion or mutation in the contralateral
MLH-1, MSH-2, MSH-6,o rPMS-2 allele. Following this,
the deﬁcient MMR (MLH-1, MSH-2, MSH-6, or PMS-2)
causes the acquisition of MI and the development of the
tumor. Inactivation of the mismatch repair gene MLH1 by
methylation of the promoter seems to be the most frequent
cause of MI in sporadic endometrioid carcinomas, followed
by a loss of the expression of other two mismatch repair
genes, the MSH2 and MSH6 genes. The mechanism for
the inactivation of MSH2 is still not clear, as promoter
methylation and mutations are rare. MSH6 inactivation is
usually caused by a mutation.
Aneuploidy is frequent in serous cancers, and is uncom-
mon in endometrioid cancer. When present, aneuploidy is
exhibited predominantly by Grade 3 tumors [45, 46]. These
data suggest that a diﬀerent type of genomic instability is
associated with the diﬀerent histopathological-type tumors.
However, in some reports, no signiﬁcant correlations were
found to exist with either the K-ras or p53 mutations [7, 11,
47].
Telomeric attrition triggers genomic instability in cer-
tain cancer types. Both EEC and NEEC cells have short
telomeres in endometrial cancer. However, only NEECs
are signiﬁcantly associated with critical telomere shortening
compared to adjacent morphologically normal epithelium,
thus suggesting that telomere shortening contributes to the
initiation of NEECs but not EECs [48]. The authors also
proposed a model in which telomere attrition gives rise to
the initiation of NEECs and the progression of EECs.
5. GeneticsEventsoutsidethe Cancer Pathway
Genetic variation acting either within or outside of the
cancer cell may determine the outcome of interaction
with exogenous or endogenous carcinogens. Endometrial
stimulation by estrogens without the diﬀerentiating eﬀects
of the progestins is a primary etiologic factor associated with
the development of endometrial hyperplasia and carcinoma
[3]. There is evidence that estrogens and some of their
metabolites are involved in the endometrial cancer patho-
genesis.Estrogensandsomeoftheirderivativesaregenotoxic
and induce DNA damage, which if not removed could, thus,
contribute to an increased risk of malignancy. Defects in the
estrogen metabolism can result in defective apoptosis, DNA
repair, and proliferation [49, 50]. Estrogens mediate their
eﬀects via the estrogen receptors (ESRs), estrogen receptor
alpha (ESR1) and estrogen receptor beta (ESR2), which
activate its metabolic pathways. The polymorphisms of ESR1
and ESR2 suggest an association with an increasing risk of
developing endometrial cancer [51]. Cytochrome P450 1B1
CYP1B1 is a constitutively expressed and inducible enzyme
with a central role in the oxidative metabolism of a wide
range of endogenous and exogenous compounds including
many carcinogens [52, 53]. Saini et al. reported that CYP1B1
depletion in endometrial cancer cells leads to decreased
cellular proliferation and induced G0-G1 cell cycle arrest,
thus suggesting that CYP1B1 inhibition in endometrial
cancer cells could be a useful therapeutic approach [54].
Progesteroneoritssyntheticformhasbeenusedasaprimary
treatment or palliative treatment of advanced and recurrence
endometrial cancer, because progesterone inhibits estrogen-
induced endometrial proliferation. In addition, the loss
of progesterone-mediated Wnt signaling inhibition in the
endometrium plays a rate-limiting role in tumor onset and
progression [55].
6. InheritedPredisposition
6.1. Lynch Syndrome. Lynch syndrome, or hereditary non-
polyposis colorectal cancer (HNPCC), is characterized by an
increasedriskforcolorectalcancer.Endometrialcanceristhe
most common malignancy in patients with Lynch syndrome
or HNPCC [56]. Lynch syndrome is caused by an inherited
mutation in the MMR gene family, such as MLH1, MSH2,
MSH6, PMS1, or PMS2 [57]. The age at diagnosis of Lynch
syndrome associated endometrial cancer is approximately 2
decades younger than that for sporadic endometrial cancers
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with endometrial cancer (median age 46) were associated
with MI, 57% of the MI positive group showed an absence
of hMLH1 expression, 19% showed an absence of hMLH2
expression, and 23.8% demonstrated a normal expression of
both proteins, while 9.5% of all patients were diagnosed with
Lynch syndrome [59]. In another report, the development
of the latter tumors of Lynch syndrome is signiﬁcantly
associated with MSH2/MSH6 protein complex deﬁciency
[60].
6.2. Familial Site-Speciﬁc Endometrial Carcinoma. The clus-
tering of endometrial carcinoma alone, termed as familial
site-speciﬁc endometrial carcinoma, may constitute a sepa-
rate entity. Eight percent of this group have been reported
to have germline MMR mutations [61]. This mutation rate
is lower than that of Lynch syndrome with endometrial
cancer patients, of whom 15% show MMR mutations [62].
The diﬀerence in MMR, mutations, therefore suggests the
existence of diﬀerent genetic alteration pathways in familial
site-speciﬁc endometrial carcinoma.
7.MalignantMixedMullerian
Tumors (MMMTs)
Carcinosarcomas (malignant mixed mullerian tumors, or
MMMTs) are currently excluded from uterine sarcoma and
classiﬁedasmetaplasticcarcinoma,andmanystudiesinclude
these as NEECs [63]. However, endometrial carcinoma and
MMMTs develop along distinctive molecular genetic path-
ways and exhibit diﬀerent biological features. In MMMT,
p53 alterations occur early, during progression, just prior to
clonal expansion and acquisition of genetic diversity [64].
In addition, changes in the AKT/β-catenin pathway may
be essential for both the establishment and maintenance of
phenotypic characteristics of MMMTs, playing key roles in
the regulation of E-cadherin through transactivation of the
Slug E-cadherin repressor gene [65]. Vaidya et al. reported
that according to the discrepancy in survival the patients of
MMMT should not be included in studies of endometrial
cancers[66].Fromthisviewpoint,futurestudieswillidentify
factors to classify these diseases.
8. De-Differentiation of Endometrioid Tumors
Mixed serous and endometrioid tumors have serous com-
ponents that may be related to the “de-diﬀerentiation”
of endometrioid tumors. This concept would explain the
presence of overlapping EEC and NEEC features, both
morphological and molecular in some tumors [67].
9. EpigeneticChanges
Aberrant CpG island hypermethylation in promoter regions
occurs in many cancer-related genes, including those asso-
ciated with cell cycle control, apoptosis, and DNA repair.
Usually, unmethylated CpG islands become methylated,
causing transcriptional silencing in cancer cells. Banno et al.
reported that the frequencies of aberrant hypermethylation
were 40.4% in hMLH1, 22% in APC, 14% in E-cadherin,
and 2.3% in RAR-β in endometrial cancer specimens [68].
However, no aberrant DNA methylation was found in the
p16 gene. Other genes inactivated by promoter hyperme-
thylation in endometrial cancer include PgR [69], the cell
cycle control genes 14-3-3 sigma [70], homeobox gene
HOXA11, thrombospondin-2 gene (THBS2) [71], paternally
expressed gene 3 (PEG3) [72], as well as the detoxifying
enzyme glutathione S-transferase P1 (GSTP1) [73]. The
impact of methylation on these genes in endometrial cancer
development has not been well established. In endometrial
cancers, diﬀerential DNA methylation patterns are detected
in EICs and NEECs, suggesting divergent epigenetic back-
grounds and unique tumorigenic pathways [74]. Promoter
hypermethylation is a frequent event in EIC but not NEECs
[75]. Many of the tumor suppressor pathways that are
mutated in EIC can also be inactivated by hypermethylation.
10. The Future
The goal of screening endometrial cancers is to identify all
patients who have a risk for developing this disease. There-
fore clariﬁcation of the molecular and genetic mechanisms
of development or progression of this disease is required.
Understanding the genetic changes underlying cancer devel-
opment or progression in the diﬀerent histological subtypes
is important for discovery of new targets for both diagnosis
and therapy for individual patients.
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